SCHEMBL3592364

SCHEMBL3592364

CCOC(=O)CN(C)CCC(C=O)Cc1ccc(C(=O)OC)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.40
ALDH1A1 P00352 4/20 0.39
NPC1 O15118 3/20 0.39
HPGD P15428 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 2/20 0.39
TSHR P16473 2/20 0.39
GAA P10253 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LOXL2 Q9Y4K0 1/20 0.37
RAB9A P51151 2/20 0.36
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP4A11 Q02928 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP4F2 P78329 1/20 0.34
HTT P42858 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6138542 0.81 CYP4Z1 (0.41) LTA4HALDH1A1NPC1SMN1; SMN2KDM4E
SCHEMBL6138595 0.81 LTA4H (0.41) LTA4HALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL3598408 0.76 LTA4H (0.44) LTA4HALDH1A1NPC1HPGDGAA
SCHEMBL3598346 0.76 LTA4H (0.44) LTA4HALDH1A1NPC1HPGDGAA
SCHEMBL3016468 0.76 CYP4A11 (0.53) ALDH1A1HPGDHSD17B10LOXL2MAPT
SCHEMBL3596235 0.75 LOXL2 (0.47) ALDH1A1NPC1HPGDSMN1; SMN2KDM4E
SCHEMBL6001848 0.74 CYP4A11 (0.44) ALDH1A1NPC1HPGDSMN1; SMN2KDM4E
SCHEMBL3594773 0.74 SMN1; SMN2 (0.44) NPC1HPGDSMN1; SMN2KDM4ETSHR
SCHEMBL3594770 0.73 CYP4A11 (0.43) ALDH1A1NPC1HPGDSMN1; SMN2KDM4E
SCHEMBL27623425 0.72 SMN1; SMN2 (0.52) ALDH1A1NPC1HPGDSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674825-B2 Dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2010-03-09 US disclosed
US-7674825-B2 Dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2010-03-09 US disclosed
US-7674825-B2 Dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2010-03-09 US disclosed
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT 2008-03-06 US disclosed
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT 2008-03-06 US disclosed
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT 2008-03-06 US disclosed
EP-1216223-B1 NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES BAYER HEALTHCARE AG (DE) 2005-11-09 EP disclosed
EP-1216223-A1 NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES Bayer Aktiengesellschaft (DE) 2002-06-26 EP disclosed
WO-2001019778-A1 NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES BAYER AKTIENGESELLSCHAFT (DE) 2001-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties PC, GOT2, SDHA LTA4H 2385/4885ALDH1A1 302/4885NPC1 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.